Flexipharm Austrading, the UK specialty pharmaceutical company focused on supplying the NHS with Better, Critical Care Medicines, today announced the commercial availability in the UK of its second differentiated generic injectable product.” Flexipharm Austrading’s Methylthioninium Chloride 10mg/ml Sterile concentrate for solution for injection is the first and only generic licensed medicinal product presentation of methylthioninium chloride to be available in a preferred vial presentation . As an MHRA licensed and European Pharmacopoeia compliant product, it meets or exceeds specifications on levels of organic and metal impurities, and has several benefits to the NHS , notably: Lower cost and fewer steps to prepare the drug for administration compared to the alternative ampoule product Removal of ‘sharps’ injury risk, often associated with opening ampoules An NHS/List price which is £46.89 per pack or 23% cheaper than the alternative ampoule product 1 Improved shelf life – can be used for up to 24 hours from opening, compared to the alternative ampoule product which must be used immediately Commenting on the launch, Michael Clark , Founder and Director of Flexipharm Austrading, said: “We are excited to be bringing this presentation of Methylthioninium Chloride to the NHS. Not only does our glass vial presentation remove the very real risk to health professionals of sharps injuries associated with opening glass ampoules, but this improved presentation offers a lower cost to the NHS and more flexibility in usage. […] For product Information: https://www.medicines.org.uk/emc/product/11181 About Flexipharm Austrading Flexipharm Austrading’s vision is to become a UK-based specialty pharmaceutical company that is genuinely respected and trusted by NHS hospitals. […] Flexipharm Austrading will be launching several products from the Phebra portfolio in the UK in 2021 and 2022.
Click here to read the full article